Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

Jon B. Toledo, Henrik Zetterberg, Argonde C. Van Harten, Lidia Glodzik, Pablo Martinez-Lage, Luisella Bocchio-Chiavetto, Lorena Rami, Oskar Hansson, Reisa Sperling, Sebastiaan Engelborghs, Ricardo S. Osorio, Hugo Vanderstichele, Manu Vandijck, Harald Hampel, Stefan Teipl, Abhay R Moghekar, Marilyn Albert, William T. Hu, Jose A. Monge Argilés, Ana Gorostidi & 12 others Charlotte E. Teunissen, Peter P. De Deyn, Bradley T. Hyman, Jose L. Molinuevo, Giovanni B. Frisoni, Gurutz Linazasoro, Mony J. De Leon, Wiesje M. Van Der Flier, Philip Scheltens, Kaj Blennow, Leslie M. Shaw, John Q. Trojanowski

Research output: Contribution to journalArticle

Abstract

In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex® measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-β1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-β amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-β1-42 and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE ε4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-β1-42 values and APOE ε2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1% at 44 years to 16% at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal fluid amyloid-β1-42 levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-β1-42, phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.

Original languageEnglish (US)
Pages (from-to)2701-2715
Number of pages15
JournalBrain
Volume138
Issue number9
DOIs
StatePublished - Sep 1 2015

Fingerprint

Amyloid
Cerebrospinal Fluid
Alzheimer Disease
Biomarkers
Genotype
Healthy Volunteers
Enzyme-Linked Immunosorbent Assay
Pathology

Keywords

  • Alzheimer's disease
  • biomarkers
  • cognitive ageing
  • dementia
  • imaging

ASJC Scopus subject areas

  • Clinical Neurology
  • Medicine(all)

Cite this

Toledo, J. B., Zetterberg, H., Van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., ... Trojanowski, J. Q. (2015). Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain, 138(9), 2701-2715. https://doi.org/10.1093/brain/awv199

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. / Toledo, Jon B.; Zetterberg, Henrik; Van Harten, Argonde C.; Glodzik, Lidia; Martinez-Lage, Pablo; Bocchio-Chiavetto, Luisella; Rami, Lorena; Hansson, Oskar; Sperling, Reisa; Engelborghs, Sebastiaan; Osorio, Ricardo S.; Vanderstichele, Hugo; Vandijck, Manu; Hampel, Harald; Teipl, Stefan; Moghekar, Abhay R; Albert, Marilyn; Hu, William T.; Monge Argilés, Jose A.; Gorostidi, Ana; Teunissen, Charlotte E.; De Deyn, Peter P.; Hyman, Bradley T.; Molinuevo, Jose L.; Frisoni, Giovanni B.; Linazasoro, Gurutz; De Leon, Mony J.; Van Der Flier, Wiesje M.; Scheltens, Philip; Blennow, Kaj; Shaw, Leslie M.; Trojanowski, John Q.

In: Brain, Vol. 138, No. 9, 01.09.2015, p. 2701-2715.

Research output: Contribution to journalArticle

Toledo, JB, Zetterberg, H, Van Harten, AC, Glodzik, L, Martinez-Lage, P, Bocchio-Chiavetto, L, Rami, L, Hansson, O, Sperling, R, Engelborghs, S, Osorio, RS, Vanderstichele, H, Vandijck, M, Hampel, H, Teipl, S, Moghekar, AR, Albert, M, Hu, WT, Monge Argilés, JA, Gorostidi, A, Teunissen, CE, De Deyn, PP, Hyman, BT, Molinuevo, JL, Frisoni, GB, Linazasoro, G, De Leon, MJ, Van Der Flier, WM, Scheltens, P, Blennow, K, Shaw, LM & Trojanowski, JQ 2015, 'Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects', Brain, vol. 138, no. 9, pp. 2701-2715. https://doi.org/10.1093/brain/awv199
Toledo JB, Zetterberg H, Van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L et al. Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. Brain. 2015 Sep 1;138(9):2701-2715. https://doi.org/10.1093/brain/awv199
Toledo, Jon B. ; Zetterberg, Henrik ; Van Harten, Argonde C. ; Glodzik, Lidia ; Martinez-Lage, Pablo ; Bocchio-Chiavetto, Luisella ; Rami, Lorena ; Hansson, Oskar ; Sperling, Reisa ; Engelborghs, Sebastiaan ; Osorio, Ricardo S. ; Vanderstichele, Hugo ; Vandijck, Manu ; Hampel, Harald ; Teipl, Stefan ; Moghekar, Abhay R ; Albert, Marilyn ; Hu, William T. ; Monge Argilés, Jose A. ; Gorostidi, Ana ; Teunissen, Charlotte E. ; De Deyn, Peter P. ; Hyman, Bradley T. ; Molinuevo, Jose L. ; Frisoni, Giovanni B. ; Linazasoro, Gurutz ; De Leon, Mony J. ; Van Der Flier, Wiesje M. ; Scheltens, Philip ; Blennow, Kaj ; Shaw, Leslie M. ; Trojanowski, John Q. / Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. In: Brain. 2015 ; Vol. 138, No. 9. pp. 2701-2715.
@article{198763ab6dfe4e4294b767f4ccb1cc27,
title = "Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects",
abstract = "In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex{\circledR} measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-β1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-β amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-β1-42 and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE ε4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-β1-42 values and APOE ε2 carriers showed the opposite effect. At 40 years of age, 76{\%} of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32{\%} at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1{\%} at 44 years to 16{\%} at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1{\%} at 53 years to 28{\%} at 85 years. Abnormally low cerebrospinal fluid amyloid-β1-42 levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-β1-42, phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.",
keywords = "Alzheimer's disease, biomarkers, cognitive ageing, dementia, imaging",
author = "Toledo, {Jon B.} and Henrik Zetterberg and {Van Harten}, {Argonde C.} and Lidia Glodzik and Pablo Martinez-Lage and Luisella Bocchio-Chiavetto and Lorena Rami and Oskar Hansson and Reisa Sperling and Sebastiaan Engelborghs and Osorio, {Ricardo S.} and Hugo Vanderstichele and Manu Vandijck and Harald Hampel and Stefan Teipl and Moghekar, {Abhay R} and Marilyn Albert and Hu, {William T.} and {Monge Argil{\'e}s}, {Jose A.} and Ana Gorostidi and Teunissen, {Charlotte E.} and {De Deyn}, {Peter P.} and Hyman, {Bradley T.} and Molinuevo, {Jose L.} and Frisoni, {Giovanni B.} and Gurutz Linazasoro and {De Leon}, {Mony J.} and {Van Der Flier}, {Wiesje M.} and Philip Scheltens and Kaj Blennow and Shaw, {Leslie M.} and Trojanowski, {John Q.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1093/brain/awv199",
language = "English (US)",
volume = "138",
pages = "2701--2715",
journal = "Brain",
issn = "0006-8950",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects

AU - Toledo, Jon B.

AU - Zetterberg, Henrik

AU - Van Harten, Argonde C.

AU - Glodzik, Lidia

AU - Martinez-Lage, Pablo

AU - Bocchio-Chiavetto, Luisella

AU - Rami, Lorena

AU - Hansson, Oskar

AU - Sperling, Reisa

AU - Engelborghs, Sebastiaan

AU - Osorio, Ricardo S.

AU - Vanderstichele, Hugo

AU - Vandijck, Manu

AU - Hampel, Harald

AU - Teipl, Stefan

AU - Moghekar, Abhay R

AU - Albert, Marilyn

AU - Hu, William T.

AU - Monge Argilés, Jose A.

AU - Gorostidi, Ana

AU - Teunissen, Charlotte E.

AU - De Deyn, Peter P.

AU - Hyman, Bradley T.

AU - Molinuevo, Jose L.

AU - Frisoni, Giovanni B.

AU - Linazasoro, Gurutz

AU - De Leon, Mony J.

AU - Van Der Flier, Wiesje M.

AU - Scheltens, Philip

AU - Blennow, Kaj

AU - Shaw, Leslie M.

AU - Trojanowski, John Q.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex® measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-β1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-β amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-β1-42 and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE ε4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-β1-42 values and APOE ε2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1% at 44 years to 16% at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal fluid amyloid-β1-42 levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-β1-42, phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.

AB - In a large multicentre sample of cognitively normal subjects, as a function of age, gender and APOE genotype, we studied the frequency of abnormal cerebrospinal fluid levels of Alzheimer's disease biomarkers including: total tau, phosphorylated tau and amyloid-β1-42. Fifteen cohorts from 12 different centres with either enzyme-linked immunosorbent assays or Luminex® measurements were selected for this study. Each centre sent nine new cerebrospinal fluid aliquots that were used to measure total tau, phosphorylated tau and amyloid-β1-42 in the Gothenburg laboratory. Seven centres showed a high correlation with the new Gothenburg measurements; therefore, 10 cohorts from these centres are included in the analyses here (1233 healthy control subjects, 40-84 years old). Amyloid-β amyloid status (negative or positive) and neurodegeneration status (negative or positive) was established based on the pathological cerebrospinal fluid Alzheimer's disease cut-off values for cerebrospinal fluid amyloid-β1-42 and total tau, respectively. While gender did not affect these biomarker values, APOE genotype modified the age-associated changes in cerebrospinal fluid biomarkers such that APOE ε4 carriers showed stronger age-related changes in cerebrospinal fluid phosphorylated tau, total tau and amyloid-β1-42 values and APOE ε2 carriers showed the opposite effect. At 40 years of age, 76% of the subjects were classified as amyloid negative, neurodegeneration negative and their frequency decreased to 32% at 85 years. The amyloid-positive neurodegeneration-negative group remained stable. The amyloid-negative neurodegeneration-positive group frequency increased slowly from 1% at 44 years to 16% at 85 years, but its frequency was not affected by APOE genotype. The amyloid-positive neurodegeneration-positive frequency increased from 1% at 53 years to 28% at 85 years. Abnormally low cerebrospinal fluid amyloid-β1-42 levels were already frequent in midlife and APOE genotype strongly affects the levels of cerebrospinal fluid amyloid-β1-42, phosphorylated tau and total tau across the lifespan without influencing the frequency of subjects with suspected non-amyloid pathology.

KW - Alzheimer's disease

KW - biomarkers

KW - cognitive ageing

KW - dementia

KW - imaging

UR - http://www.scopus.com/inward/record.url?scp=84940769248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940769248&partnerID=8YFLogxK

U2 - 10.1093/brain/awv199

DO - 10.1093/brain/awv199

M3 - Article

VL - 138

SP - 2701

EP - 2715

JO - Brain

JF - Brain

SN - 0006-8950

IS - 9

ER -